3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Gastroparesis
1
Esophageal Motility Disorders
1
Esophageal Diseases
1
Esophageal Achalasia
1
Interventions
Oxaliplatin
49
Fluorouracil
46
Capecitabine
41
Cisplatin
36
Gemcitabine
29
Leucovorin
27
Bevacizumab
21
Drug Therapy
20
Paclitaxel
15
Folfox protocol
15
Radiotherapy
14
Irinotecan
14
apatinib
11
Neoadjuvant Therapy
11
Docetaxel
11
sintilimab
9
S 1 (combination)
9
Sorafenib
8
Nivolumab
8
Trastuzumab
7
Surgical Procedures, Operative
7
Magnetic Resonance Spectroscopy
7
lenvatinib
6
atezolizumab
6
XELOX
6
Cetuximab
6
Albumin-Bound Paclitaxel
6
130-nm albumin-bound paclitaxel
6
tislelizumab
5
pembrolizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Botulinum Toxins, Type A
×
Gastrointestinal
×
Clear all
NCT06721520
2026-02-25
EMPTY
The Cleveland Clinic
Phase 2/3
Recruiting
170 enrolled